MyOme Demonstrates Clinical Validity of Integrated Polygenic and Clinical Risk Prediction for Coronary Artery Disease
Findings come as ACC/AHA guidelines recognize polygenic risk as an ASCVD risk enhancer MENLO PARK, Calif., March 20, 2026 - MyOme, a leader in clinical whole-genome analysis and integrated risk modeling, today announced research showing that integ...
